Morling Financial Advisors’s AbbVie ABBV Stock Holding History

Morling Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	984 +4	+0.4%	+$861	0.07%	70
2026 Q1	$213K	Sell	980 -7	-0.7%	-$1.55K	0.07%	71
2025 Q4	$226K	Buy	987 +7	+0.7%	+$1.59K	0.07%	71
2025 Q3	$227K	Buy	+980	New	+$200K	0.08%	64
2025 Q2	–	Sell	-1,370	Closed	-$287K	–	103
2025 Q1	$287K	Buy	+1,370	New	+$266K	0.1%	71
2024 Q2	–	Sell	-1,376	Closed	-$251K	–	91
2024 Q1	$251K	Sell	1,376 -252	-15%	-$43.4K	0.14%	61
2023 Q4	$252K	Buy	1,628 +9	+0.6%	+$1.31K	0.2%	50
2023 Q3	$241K	Sell	1,619 -54	-3%	-$7.93K	0.24%	46
2023 Q2	$225K	Sell	1,673 -22	-1%	-$3.23K	0.22%	48
2023 Q1	$270K	Sell	1,695 -149	-8%	-$22.8K	0.29%	42
2022 Q4	$298K	Sell	1,844 -313	-15%	-$48K	0.38%	38
2022 Q3	$290K	Buy	2,157 +5	+0.2%	+$717	0.39%	37
2022 Q2	$330K	Sell	2,152 -104	-5%	-$15.9K	0.43%	38
2022 Q1	$366K	Buy	2,256 +214	+10%	+$31.1K	0.46%	33
2021 Q4	$277K	Buy	+2,042	New	+$241K	0.27%	38

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morling Financial Advisors's ABBV Position: Q2 2026 in Review

Morling Financial Advisors increased its AbbVie (ABBV) stake by 0.41% in Q2 2026, buying an estimated $861 and bringing the position to 984 shares worth $248K. The position accounts for 0.07% of the portfolio, ranked #70.

Morling Financial Advisors first reported a position in ABBV in Q4 2021 and has held it in 15 quarters since. The position peaked at $366K in Q1 2022. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Morling Financial Advisors held 984 shares of AbbVie worth $248K as of Q2 2026.
Morling Financial Advisors bought 4 AbbVie shares in Q2 2026, an estimated $861.
AbbVie made up 0.07% of Morling Financial Advisors's portfolio in Q2 2026, its #70 holding.
Morling Financial Advisors first reported a position in AbbVie in Q4 2021 and has held it in 15 quarters since.
Morling Financial Advisors's AbbVie position peaked at $366K in Q1 2022.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Morling Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.